1、novotech-AUGUST 12,2024Diffuse Large B-Cell Lymphoma-Global Clinical Trial Landscape(2024)The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,o

2、r other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other mater

3、ials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?Marketed dru

4、gs for DLBCL,including Ritux-imab and its biosimilars,as well as Polatuzumab Vedotin and Tafasitam-ab,are widely available across the United States,Europe,and AsiaPhase III trials for Mosunetuzumab and Selinexor are progress-ing globally,ofering promising advance-ments and potential new treatment op

5、tions for DLBCLDIFFUSE LARGE B-CELL LYMPHOMA(DLBCL)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)In the Asia-Pacific region,China reported an estimated higher incidence of DLBCL casesThe United States had the highest estimated number of DLBCL cases in North AmericaIn Europe,Germany reported an estimated high

6、er incidence of DLBCLIn ROW,Brazil reported the highest incidence of DLBCLDLBCL is the most common and ag-gressive subtype of non-Hodgkin lympho-ma(NHL),account-ing for 30-40%of all NHL cases world-wideThe Asia-Pacific region shows recruitment rates comparable to those of the United StatesDIFFUSE LA